Leendert A Trouw

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/89143/publications.pdf

Version: 2024-02-01

219 papers	9,826 citations	30070 54 h-index	43889 91 g-index
255 all docs	255 docs citations	255 times ranked	9423 citing authors

#	Article	IF	Citations
1	Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17372-17377.	7.1	464
2	Production of complement components by cells of the immune system. Clinical and Experimental Immunology, 2017, 188, 183-194.	2.6	350
3	Complement activation and inhibition: a delicate balance. Trends in Immunology, 2009, 30, 83-90.	6.8	304
4	Citrullinated peptide dendritic cell immunotherapy in HLA risk genotypeâ€“positive rheumatoid arthritis patients. Science Translational Medicine, 2015, 7, 290ra87.	12.4	302
5	Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. European Journal of Immunology, 2002, 32, 1726.	2.9	276
6	Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 234-241.	0.9	225
7	Antiâ€“cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis and Rheumatism, 2009, 60, 1923-1931.	6.7	212
8	Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 780-783.	0.9	185
9	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. Journal of Clinical Investigation, 2004, 114, 679-688.	8.2	185
10	Glycan profiling of antiâ€“citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis and Rheumatism, 2010, 62, 1620-1629.	6.7	183
11	The influence of ACPA status and characteristics on the course of RA. Nature Reviews Rheumatology, 2012, 8, 144-152.	8.0	173
12	Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population. Frontiers in Immunology, 2018, 9, 2664.	4.8	165
13	Role of complement and complement regulators in the removal of apoptotic cells. Molecular Immunology, 2008, 45, 1199-1207.	2.2	164
14	Brief Report: Antiâ€“Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 911-915.	6.7	164
15	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 578-585.	0.9	161
16	Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood, 2004, 103, 3813-3820.	1.4	157
17	The complement system as a potential therapeutic target in rheumatic disease. Nature Reviews Rheumatology, 2017, 13, 538-547.	8.0	147
18	Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation. Journal of Immunology, 2008, 180, 7613-7621.	0.8	128

#	Article	IF	Citations
19	The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells. Journal of Biological Chemistry, 2007, 282, 10894-10900.	3.4	126
20	Antibody Response Against the Glomerular Basement Membrane Protein Agrin in Patients with Transplant Glomerulopathy. American Journal of Transplantation, 2005, 5, 383-393.	4.7	125
21	Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmunity Reviews, 2012, 12, 318-322.	5.8	124
22	Complement activation by (auto-) antibodies. Molecular Immunology, 2011, 48, 1656-1665.	2.2	122
23	Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Annals of the Rheumatic Diseases, 2011, 70, 188-193.	0.9	118
24	C4b-binding Protein and Factor H Compensate for the Loss of Membrane-bound Complement Inhibitors to Protect Apoptotic Cells against Excessive Complement Attack. Journal of Biological Chemistry, 2007, 282, 28540-28548.	3.4	117
25	Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Annals of the Rheumatic Diseases, 2014, 73, 1761-1768.	0.9	111
26	Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nature Reviews Rheumatology, 2017, 13, 331-339.	8.0	109
27	Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis. Journal of Rheumatology, 2015, 42, 572-579.	2.0	107
28	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. Journal of Clinical Investigation, 2004, 114, 679-688.	8.2	104
29	Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Research and Therapy, 2015, 17, 25.	3.5	103
30	Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmunity Reviews, 2014, 13, 225-230.	5.8	99
31	Regulation of Complement Activation by C-Reactive Protein: Targeting of the Inhibitory Activity of C4b-Binding Protein. Journal of Immunology, 2006, 176, 7612-7620.	0.8	98
32	Avidity maturation of antiâ€“citrullinated protein antibodies in rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 1323-1328.	6.7	93
33	C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. Journal of Experimental Medicine, 2005, 201, 1937-1948.	8.5	92
34	Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides. Journal of Immunology, 2001, 167, 7052-7059.	0.8	84
35	Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Current Opinion in Nephrology and Hypertension, 2003, 12, 619-624.	2.0	83
36	Triple Positivity for Antiâ€“Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Antiâ€“Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1721-1731.	5.6	81

#	Article	IF	Citations
37	The C4b-binding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells. Journal of Biological Chemistry, 2004, 279, 23869-23873.	3.4	78
38	Role of complement in innate immunity and host defense. Immunology Letters, 2011, 138, 35-37.	2.5	76
39	A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Molecular Immunology, 2007, 44, 1835-1844.	2.2	73
40	Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the â€˜AMC-Senshuâ€™ method. Annals of the Rheumatic Diseases, 2013, 72, 148-150.	0.9	73
41	Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Annals of the Rheumatic Diseases, 2017, 76, 1184-1190.	0.9	73
42	Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Annals of the Rheumatic Diseases, 2011, 70, 373-379.	0.9	69
43	Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1259-1263.	0.9	69
44	The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Research and Therapy, 2015, 17, 339.	3.5	67
45	The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Annals of the Rheumatic Diseases, 2017, 76, 112-118.	0.9	67
46	Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 209.	3.5	63
47	The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Annals of the Rheumatic Diseases, 2012, 71, 268-274.	0.9	61
48	Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 43.	3.5	61
49	Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. Molecular Immunology, 2010, 47, 2129-2137.	2.2	60
50	Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clinical and Experimental Immunology, 2003, 132, 32-39.	2.6	59
51	Rheumatoid arthritisâ€“associated autoantibodies in nonâ€“rheumatoid arthritis patients with mucosal inflammation: a caseâ€“control study. Arthritis Research and Therapy, 2015, 17, 174.	3.5	59
52	Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. European Journal of Immunology, 2010, 40, 172-185.	2.9	58
53	Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Research and Therapy, 2012, 14, R185.	3.5	57
54	Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production. Frontiers in Immunology, 2017, 8, 285.	4.8	57

#	Article	IF	Citations
55	Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clinical and Experimental Immunology, 2003, 134, 335-343.	2.6	56
56	The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis and Rheumatism, 2011, 63, 1823-1832.	6.7	55
57	Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences. Frontiers in Immunology, 2013, 4, 117.	4.8	55
58	A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. British Journal of Rheumatology, 2005, 44, 111-119.	2.3	54
59	Genetic, molecular and functional analyses of complement factor I deficiency. European Journal of Immunology, 2009, 39, 310-323.	2.9	53
60	A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. Annals of the Rheumatic Diseases, 2011, 70, 2184-2190.	0.9	53
61	C1q, antibodies and anti-C1q autoantibodies. Molecular Immunology, 2015, 68, 6-13.	2.2	53
62	Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Annals of the Rheumatic Diseases, 2016, 75, 1924-1932.	0.9	53
63	Autoantibodies against complement components and functional consequences. Molecular Immunology, 2013, 56, 213-221.	2.2	52
64	The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia. Rheumatology, 2017, 56, 2145-2153.	1.9	50
65	Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue. Journal of Neuroimmunology, 2015, 278, 271-276.	2.3	48
66	C4b-binding protein in Alzheimer's disease: Binding to AÎ²1â€“42 and to dead cells. Molecular Immunology, 2008, 45, 3649-3660.	2.2	46
67	Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1461-1464.	0.9	45
68	Biomarkers for rheumatoid and psoriatic arthritis. Clinical Immunology, 2015, 161, 2-10.	3.2	45
69	Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. Kidney International, 2005, 68, 2091-2102.	5.2	44
70	TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey. Human Immunology, 2011, 72, 1210-1213.	2.4	44
71	Autoimmunity in rheumatoid arthritis: different antigensâ€"common principles. Annals of the Rheumatic Diseases, 2013, 72, ii132-ii136.	0.9	44
72	Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. Molecular Immunology, 2007, 44, 3608-3614.	2.2	43

#	Article	IF	Citations
73	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Research and Therapy, 2016, 18, 285.	3.5	43
74	Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Research and Therapy, 2016, 18, 289.	3.5	43
75	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. Frontiers in Immunology, 2018, 9, 2427.	4.8	43
76	Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. Clinical and Experimental Immunology, 2013, 173, 76-83.	2.6	41
77	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2016, 75, 1139-1144.	0.9	41
78	Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 270-276.	0.9	40
79	Autoantibodies to complement components. Molecular Immunology, 2001, 38, 199-206.	2.2	39
80	Both Complement and IgG Fc Receptors Are Required for Development of Attenuated Antiglomerular Basement Membrane Nephritis in Mice. Journal of Immunology, 2009, 183, 3980-3988.	0.8	39
81	Baseline autoantibody profile in rheumatoid arthritisÂis associated with early treatment response but not long-term outcomes. Arthritis Research and Therapy, 2018, 20, 33.	3.5	39
82	Anti-C1q autoantibodies in murine lupus nephritis. Clinical and Experimental Immunology, 2004, 135, 41-48.	2.6	38
83	Complement production and regulation by dendritic cells: Molecular switches between tolerance and immunity. Molecular Immunology, 2008, 45, 4064-4072.	2.2	37
84	Complement Activation in Patients With Diabetic Nephropathy. Kidney International Reports, 2018, 3, 302-313.	0.8	37
85	Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis. PLoS ONE, 2014, 9, e102163.	2.5	37
86	Role of Antiâ€“Carbamylated Protein Antibodies Compared to Antiâ€“Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their Firstâ€Degree Relatives, and Healthy Controls. Arthritis and Rheumatology, 2016, 68, 2090-2098.	5.6	36
87	Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Annals of the Rheumatic Diseases, 2017, 76, 716-720.	0.9	35
88	The production and secretion of complement component C1q by human mast cells. Molecular Immunology, 2016, 78, 164-170.	2.2	34
89	Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. Journal of Autoimmunity, 2017, 80, 77-84.	6.5	34
90	Pitfalls in the detection of citrullination and carbamylation. Autoimmunity Reviews, 2018, 17, 136-141.	5.8	34

#	Article	IF	Citations
91	Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification. Annals of the Rheumatic Diseases, 2019, 78, 908-916.	0.9	34
92	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. Journal of Autoimmunity, 2015, 62, 39-44.	6.5	33
93	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Research and Therapy, 2019, 21, 28.	3.5	33
94	Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation. Annals of the Rheumatic Diseases, 2016, 75, 1575-1576.	0.9	32
95	Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. Lupus, 2016, 25, 878-888.	1.6	31
96	Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opinion on Biological Therapy, 2005, 5, 243-251.	3.1	30
97	C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus. Frontiers in Immunology, 2016, 7, 647.	4.8	30
98	New biomarkers in rheumatoid arthritis. Netherlands Journal of Medicine, 2012, 70, 392-9.	0.5	30
99	Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis. Journal of Rheumatology, 2015, 42, 1786-1793.	2.0	29
100	Analysis of Binding Sites on Complement Factor I That Are Required for Its Activity. Journal of Biological Chemistry, 2010, 285, 6235-6245.	3.4	28
101	Breach of autoreactive B cell tolerance by post-translationally modified proteins. Annals of the Rheumatic Diseases, 2017, 76, 1449-1457.	0.9	27
102	Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. Clinical Rheumatology, 2017, 36, 1487-1492.	2.2	27
103	Complement and renal disease. Molecular Immunology, 2003, 40, 125-134.	2.2	26
104	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. Modern Rheumatology, 2012, 22, 15-20.	1.8	26
105	Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent: Fig. 1. Rheumatology, 2015, 54, 1930-1932.	1.9	25
106	Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. Annals of the Rheumatic Diseases, 2013, 72, 2053-2055.	0.9	24
107	Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG. Molecular Immunology, 2003, 40, 595-602.	2.2	23
108	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Research and Therapy, 2017, 19, 115.	3.5	23

#	Article	IF	Citations
109	Complement Inhibitor C4bâ€Binding Protein in Primary SjÃ¶grenâ€™s Syndrome and its Association With Other Disease Markers. Scandinavian Journal of Immunology, 2009, 69, 374-380.	2.7	22
110	Excretions/secretions from medicinal larvae (Lucilia sericata) inhibit complement activation by two mechanisms. Wound Repair and Regeneration, 2017, 25, 41-50.	3.0	22
111	Secretory form of rheumatoid arthritisâ€“associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. Annals of the Rheumatic Diseases, 2019, 78, 146-148.	0.9	22
112	Circulating C1q levels in health and disease, more than just a biomarker. Molecular Immunology, 2021, 140, 206-216.	2.2	22
113	The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. Annals of the Rheumatic Diseases, 2013, 72, 1059-1063.	0.9	21
114	An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. Arthritis Research and Therapy, 2015, 17, 276.	3.5	21
115	C1q-Dependent Dendritic Cell Cross-Presentation of In Vivoâ€“Formed Antigenâ€“Antibody Complexes. Journal of Immunology, 2017, 198, 4235-4243.	0.8	21
116	The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Arthritis Research and Therapy, 2017, 19, 190.	3.5	20
117	Complement activation and regulation in rheumatic disease. Seminars in Immunology, 2019, 45, 101339.	5.6	20
118	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. Molecular Immunology, 2020, 120, 187-195.	2.2	19
119	Activation of the lectin pathway in murine lupus nephritis. Molecular Immunology, 2005, 42, 731-740.	2.2	18
120	The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA. Arthritis Research and Therapy, 2011, 13, R195.	3.5	17
121	MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. Arthritis Research and Therapy, 2016, 18, 179.	3.5	17
122	C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation. Clinical Immunology, 2010, 135, 490-495.	3.2	16
123	Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. Annals of the Rheumatic Diseases, 2015, 74, 949-950.	0.9	16
124	Complement component C1q is produced by isolated articular chondrocytes. Osteoarthritis and Cartilage, 2020, 28, 675-684.	1.3	16
125	C4b-Binding Protein Is Present in Affected Areas of Myocardial Infarction during the Acute Inflammatory Phase and Covers a Larger Area than C3. PLoS ONE, 2008, 3, e2886.	2.5	15
126	Identification of a novel non-coding mutation in C1qB in a Dutch child with C1q deficiency associated with recurrent infections. Immunobiology, 2015, 220, 422-427.	1.9	15

#	Article	IF	Citations
127	Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis. Arthritis Research and Therapy, 2017, 19, 246.	3.5	15
128	The role of complement activation in autoimmune liver disease. Autoimmunity Reviews, 2020, 19, 102534.	5.8	15
129	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. Modern Rheumatology, 2012, 22, 15-20.	1.8	15
130	The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. Annals of the Rheumatic Diseases, 2018, 77, 1087-1088.	0.9	14
131	Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. Kidney International, 2019, 96, 738-749.	5.2	14
132	Presence of Autoantibodies in Erosive Hand Osteoarthritis and Association with Clinical Presentation. Journal of Rheumatology, 2019, 46, 101-105.	2.0	14
133	Auto-antibodies to post-translationally modified proteins in osteoarthritis. Osteoarthritis and Cartilage, 2021, 29, 924-933.	1.3	14
134	Novel genetic association of theVTCN1region with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, 567-571.	0.9	13
135	Predictive factors of radiological progression after 2â€…years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. RMD Open, 2016, 2, e000172.	3.8	13
136	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. Annals of the Rheumatic Diseases, 2018, 77, 1836-1838.	0.9	12
137	Autoantibodies are major predictors of arthritis development in patients with anti-citrullinated protein antibodies and musculoskeletal pain. Scandinavian Journal of Rheumatology, 2021, 50, 189-197.	1.1	12
138	HLAâ€“B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Antiâ€“Carbamylated Protein Antibodyâ€“Positive/Antiâ€“Cyclic Citrullinated Peptideâ€“Negative Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 963-969.	5.6	12
139	Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load. Arthritis Research and Therapy, 2021, 23, 230.	3.5	12
140	The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching. Rheumatology, 2018, 57, 1583-1591.	1.9	11
141	Systemic and pulmonary C1q as biomarker of progressive disease in experimental non-human primate tuberculosis. Scientific Reports, 2020, 10, 6290.	3.3	11
142	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Lancet, The, 2015, 385, S44.	13.7	10
143	Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls. Clinical and Experimental Rheumatology, 2021, 39, 570-577.	0.8	10
144	The major risk alleles of age-related macular degeneration (AMD) in CFH do not play a major role in rheumatoid arthritis (RA). Clinical and Experimental Immunology, 2011, 166, 333-337.	2.6	9

#	Article	IF	Citations
145	Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example. Arthritis Research and Therapy, 2018, 20, 94.	3.5	9
146	Carbamylation reduces the capacity of IgG for hexamerization and complement activation. Clinical and Experimental Immunology, 2020, 200, 1-11.	2.6	9
147	Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. RMD Open, 2022, 8, e002079.	3.8	9
148	Autoantibody testing to predict response to therapy in RA. Nature Reviews Rheumatology, 2016, 12, 566-568.	8.0	8
149	Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines). Rheumatology, 2021, 60, 658-666.	1.9	7
150	Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study. International Journal of Molecular Sciences, 2021, 22, 6763.	4.1	7
151	The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. Annals of the Rheumatic Diseases, 2011, 70, 1697-1698.	0.9	6
152	Short article. European Journal of Gastroenterology and Hepatology, 2017, 29, 345-348.	1.6	6
153	Antiâ€“Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritisâ€”A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al. Arthritis and Rheumatology, 2018, 70, 2096-2097.	5.6	6
154	The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis. Current Opinion in Rheumatology, 2019, 31, 3-8.	4.3	6
155	Serum autoantibodies directed against transglutaminase-2 have a low avidity compared with alloantibodies against gliadin in coeliac disease. Clinical and Experimental Immunology, 2014, 177, 86-93.	2.6	5
156	Inverse correlation between serum complement component C1q levels and whole blood typeâ€1 interferon signature in active tuberculosis and QuantiFERONâ€positive uveitis: implications for diagnosis. Clinical and Translational Immunology, 2020, 9, e1196.	3.8	5
157	SAT0585â€…GEO-EPIDEMIOLOGY OF AUTOANTIBODIES IN RA: DIFFERENT PREVALENCES IN FOUR ETHNICALLY DIVERSE RA POPULATIONS. Annals of the Rheumatic Diseases, 2020, 79, 1251.1-1252.	0.9	5
158	Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells. European Journal of Immunology, 2022, , .	2.9	5
159	Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls. Clinical and Experimental Rheumatology, 2021, 39, 570-577.	0.8	5
160	B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. JHEP Reports, 2022, 4, 100460.	4.9	5
161	THU0114â€…Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate in the Avert Trial. Annals of the Rheumatic Diseases, 2015, 74, 234.3-235.	0.9	4
162	Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al.. Arthritis Research and Therapy, 2020, 22, 85.	3.5	4

#	Article	IF	Citations
163	Anti-CCP antibodies are a collection of ACPA that are cross-reactive to multiple citrullinated antigens. Annals of the Rheumatic Diseases, 2010, 69, A8-A8.	0.9	3
164	The interaction between HLA SE alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Annals of the Rheumatic Diseases, 2011, 70, A1-A1.	0.9	3
165	Complex medical history of a patient with a compound heterozygous mutation inC1QC. Lupus, 2019, 28, 1255-1260.	1.6	3
166	Genetic variants of C1q are a risk for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A17-A17.	0.9	2
167	ACPA production by circulating B cells isolated from peripheral blood of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A33.1-A33.	0.9	2
168	A5.4â€…Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A31.2-A31.	0.9	2
169	Identification of Lifelines participants at high risk for development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, e43-e43.	0.9	2
170	Screening for two or three autoantibodies in persons at risk for RA: implications of current data for clinical practice. Rheumatology, 2019, 58, 914-915.	1.9	2
171	Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency. Arthritis Research and Therapy, 2020, 22, 248.	3.5	2
172	Regulation of complement activation by C-reactive protein: Targeting of the inhibitory activity of C4b-binding protein. Molecular Immunology, 2007, 44, 241.	2.2	1
173	Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. Molecular Immunology, 2008, 45, 4138-4139.	2.2	1
174	Genetic association and functional consequences of a common SNP in the CD40 region with systemic lupus erythematosus and rheumatoid arthritis in a homogeneous Greek population. Annals of the Rheumatic Diseases, 2011, 70, A14-A14.	0.9	1
175	Which elements of the criteria for RA are stable over time?. Rheumatology, 2011, 50, 248-249.	1.9	1
176	AB0096â€…Presence of systemic arthritis autoantibodies in non-ra patients with severe periodontitis. Annals of the Rheumatic Diseases, 2013, 72, A814.4-A815.	0.9	1
177	A5.14â€…Homocitrulline-Reactive Antibodies can be Generated from Synovial B-Cells from ACPA-Negative RA Patients. Annals of the Rheumatic Diseases, 2013, 72, A35.1-A35.	0.9	1
178	A1.28â€…Anti-carp antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors and smoking. Annals of the Rheumatic Diseases, 2014, 73, A11.3-A12.	0.9	1
179	A1.55â€…Development of antibodies specific for carbamylated protein precedes disease onset in MICE with collagen-induced arthritis. Annals of the Rheumatic Diseases, 2014, 73, A23.2-A24.	0.9	1
180	Reply. Arthritis and Rheumatology, 2016, 68, 2826-2827.	5.6	1

#	Article	IF	Citations
181	Complement component C1q as serum biomarker to detect active tuberculosis. Molecular Immunology, 2018, 102, 185.	2.2	1
182	Molecular and functional analysis of complement factor I mutations in atypical haemolytic uraemic syndrome patients. Molecular Immunology, 2008, 45, 4131.	2.2	0
183	Anti-citrullinated protein antibodies have a low avidity compared to antibodies against recall-antigens. Annals of the Rheumatic Diseases, 2010, 69, A7-A7.	0.9	0
184	The major risk alleles of age related macular degeneration in CFH, do not play a major role in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A17-A18.	0.9	0
185	Distinct ACPA fine-specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A5-A5.	0.9	0
186	Low avidity anti-citrullinated protein antibodies (ACPA) are associated with high radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A60-A60.	0.9	0
187	Genetic variants of C1q are a risk for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A54.1-A54.	0.9	0
188	The â€˜Senshuâ€™ method often used to detect citrullinated proteins does not discriminate between citrullination and carbamylation. Annals of the Rheumatic Diseases, 2012, 71, A40.2-A40.	0.9	0
189	The ACPA IgM fine specificity differs from the ACPA IgG antigen-recognition profile. Annals of the Rheumatic Diseases, 2012, 71, A33.2-A33.	0.9	0
190	FRI0005â€…Production of anti-citrullinated protein antibodies by B cell subsets isolated from peripheral blood of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 312.2-312.	0.9	0
191	A5.29â€…Spontaneous Production of Anti-Citrullinated Protein Antibodies in Cultures of Peripheral Blood Mononuclear Cells and Synovial Fluid Mononuclear Cells Isolated from Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A41.1-A41.	0.9	0
192	A5.6â€…Anti-Carbamylated Protein Antibodies are Present in Mice with Collagen induced Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A32.1-A32.	0.9	0
193	A1.45â€…Hyperglycosylation of ACPA-IGG variable domains modulates reactivity to citrullinated antigens. Annals of the Rheumatic Diseases, 2014, 73, A19.2-A19.	0.9	0
194	FRI0402â€…Cluster Analysis of an ARRAY of Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Annals of the Rheumatic Diseases, 2014, 73, 532.3-533.	0.9	0
195	A1.49â€…Anti-carbamylated protein antibodies (ANTI-CARP) precede the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A21.1-A21.	0.9	0
196	Five decades of Dutch immunology. Immunology Letters, 2014, 162, 83-84.	2.5	0
197	A1.29â€…In rheumatoid arthritis, smoking is not primarily associated with anti-citrullinaged protein antibodies, but with the presence of several autoantibodies. Annals of the Rheumatic Diseases, 2014, 73, A12.1-A12.	0.9	0
198	A7.4â€…The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Annals of the Rheumatic Diseases, 2015, 74, A76.1-A76.	0.9	0

#	Article	IF	Citations
199	THU0040â€…In Rheumatoid Arthritis, Smoking is not Associated with Anti-Citrullinated Protein Antibodies (ACPA) Per SE, but with the Concurrent Presence of Rheumatoid Factor, Acpa and Anti-Carbamylated Protein Antibodies. Annals of the Rheumatic Diseases, 2015, 74, 206.4-207.	0.9	0
200	AB0086â€…Anti-Citrullinated Protein Antibodies in Patients with Cardiovascular Disease without RA. Annals of the Rheumatic Diseases, 2016, 75, 926.1-926.	0.9	0
201	A2.05â€…Carbamylated autoantigens facilitate the break of tolerance: A novel mechanism in the pathogenesis of autoimmune arthritis. Annals of the Rheumatic Diseases, 2016, 75, A17.1-A17.	0.9	0
202	A2.10â€…The isotype and subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2016, 75, A19.1-A19.	0.9	0
203	Excretions/secretions from medicinal larvae (Lucilia sericata) inhibit complement activation by two mechanisms. Immunobiology, 2016, 221, 1137.	1.9	0
204	A5.09â€…Mri-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. Annals of the Rheumatic Diseases, 2016, 75, A44.3-A45.	0.9	0
205	A2.15â€…Ra phenotype at presentation differs among patients with few versus many autoantibodies. Annals of the Rheumatic Diseases, 2016, 75, A21.1-A21.	0.9	0
206	AB0066â€…MRI-Detected Osteitis Is Not Associated with The Presence or Level of ACPA Alone, but with The Combined Presence of ACPA and RF. Annals of the Rheumatic Diseases, 2016, 75, 919.2-920.	0.9	0
207	08.26â€…The prevalence of acpa is lower in rheumatoid arthritis patients with a higher age of onset but the composition of the acpa response appears identical. , 2017, , .		0
208	THU0068â€…The risk of individual autoantibodies, autoantibody combinations and autoantibody levels for arthritis development in clinically suspect arthralgia. , 2017, , .		0
209	AB0084â€…Breadth of baseline autoantibody profile and treatment response in rheumatoid arthritis patients. , 2017, , .		0
210	Complement System. , 2017, , 355-365.		0
211	P026â€…Baseline autoantibody profile in rheumatoid arthritis associates with early treatment response but not long-term outcomes. , 2018, , .		0
212	P007â€…In ra, becoming seronegative over the 1st year of dmard treatment does not translate to better chances of drug-free remission in the long-term. , 2018, , .		0
213	SAT0579â€…Presence of autoantibodies in erosive hand osteoarthritis and association with clinical presentation. , 2018, , .		0
214	AB0113â€…ANTI-CARBAMYLATED PROTEIN ANTIBODIES POSITIVITY AND DISEASE ACTIVITY IN HISPANIC PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1085-1086.	0.9	0
215	Antiâ€C1q autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a singleâ€centre, crossâ€sectional study. British Journal of Dermatology, 2021, 185, 657-658.	1.5	0
216	Anti-carbamylated protein antibodies positivity and disease activity in Hispanic patients with established rheumatoid arthritis: An observational study. Modern Rheumatology, 2022, 32, 330-337.	1.8	0

#	Article	IF	Citations
217	FRI0337â€…anti-C1Q Autoantibodies, C1Q Circulating Immune Complexes and Complement Levels in Patients with Neuropsychiatric Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 556.3-557.	0.9	0
218	THU0069â€…In ra, becoming seronegative over the 1st year of dmard treatment does not translate to better chances of sustained drug-free remission in the long-term. , 2018, , .		0
219	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. Clinical and Experimental Rheumatology, 2021, 39, 146-150.	0.8	0